Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Next Previous
Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hepatitis A vaccine inactivated; Hib-DTaP-hepatitis B-poliovirus vaccine; Hib-DTP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine-(Priorix); Measles mumps and rubella virus vaccine-(Priorix); Measles vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Poliovirus vaccine inactivated; Rotavirus W179-9 vaccine; Typhoid vaccine Vi conjugate; Varicella zoster virus vaccine live
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 25 Nov 2024 Planned End Date changed from 8 Sep 2025 to 2 Dec 2025.
  • 25 Nov 2024 Planned primary completion date changed from 8 Sep 2025 to 2 Dec 2025.
  • 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top